Collectively, these findings highlight ponatinib’s superior activity against NSCLC RET fusions tested (KIF5B-RET, NCOA4-RET, and CCDC6-RET) in comparison with a broad range of TKIs, including those that are currently being most actively evaluated in NSCLC (cabozantinib and vandetanib). This evidence concerns the gene NCOA4 and non-small cell lung carcinoma.